Effective Clinical Responses in @entity320 XXXX after Vaccination with Primary Myeloid Dendritic Cells.

@entity1 @entity137 @entity9857 @entity3220 @entity5 @entity310 @entity4897 @entity12868 @entity3 @entity11442 @entity320
PURPOSE: Thus far, dendritic cell (DC)-based immunotherapy of @entity5 was primarily based on in vitro-generated monocyte-derived DCs, which require extensive in vitro manipulation. Here, we report on a clinical study exploiting primary @entity4897 (+) myeloid DCs, naturally circulating in the blood. EXPERIMENTAL DESIGN: Fourteen stage IV @entity320 @entity1 , without previous systemic treatment for @entity3 , received autologous @entity4897 (+) myeloid DCs, activated by only brief (16 hours) ex vivo culture and loaded with @entity5 -associated antigens of @entity11442 and @entity9857 . RESULTS: Our results show that therapeutic vaccination against @entity320 with small amounts (3-10 * 10(6)) of myeloid DCs is feasible and without substantial @entity137 . Four of 14 @entity1 showed long-term progression-free survival (12-35 months), which directly correlated with the development of multifunctional CD8(+) T-cell responses in three of these @entity1 . In particular, high @entity3220 expression, indicative for cytolytic activity, and IFNy as well as @entity310 and @entity12868 production was observed. Apparently, these T-cell responses are essential to induce @entity5 regression and promote long-term survival by stalling @entity5 growth. CONCLUSIONS: We show that vaccination of @entity320 @entity1 with primary myeloid DCs is feasible and safe and results in induction of effective antitumor immune responses that coincide with improved progression-free survival. Clin Cancer Res; 22(9); 2155-66.   2015 AACR.
